MCK241004C502500
- 0.03
- -0.22-88.00%
McKesson Newsroom
Argus Research Maintains McKesson(MCK.US) With Buy Rating, Announces Target Price $570
Argus Adjusts Price Target on McKesson to $570 From $640
Deutsche Bank Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $579
Deutsche Bank Maintains Buy on McKesson, Lowers Price Target to $579
Buy Rating Affirmed: McKesson's Long-term Growth Strategy Balances Short-term Earnings Concerns
McKesson Price Target Cut to $531.00/Share From $603.00 by Baird
Baird Downgrades McKesson(MCK.US) to Hold Rating, Cuts Target Price to $531
McKesson: Operational and Strategic Challenges Prompt Hold Rating
McKesson Analyst Ratings
Wells Fargo Maintains Equal-Weight on McKesson, Lowers Price Target to $535
Deutsche Bank Trims Price Target on McKesson to $623 From $631
Leerink Partners Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $665
Michael Cherny Reaffirms Buy Rating on McKesson Amid Temporary Setbacks and Long-Term Growth Prospects
Wells Fargo Maintains McKesson(MCK.US) With Hold Rating, Cuts Target Price to $535
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)
McKesson Is Maintained at Buy by Citigroup
McKesson Analyst Ratings
Jefferies Adjusts Price Target on McKesson to $607 From $630
Citi Maintains McKesson(MCK.US) With Buy Rating, Cuts Target Price to $630
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $616